Prosight Management as of March 31, 2022
Portfolio Holdings for Prosight Management
Prosight Management holds 32 positions in its portfolio as reported in the March 2022 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Galapagos Nv Spon Adr (GLPG) | 15.0 | $23M | 374k | 62.02 | |
Prothena Corp SHS (PRTA) | 13.4 | $21M | 567k | 36.57 | |
Albireo Pharma | 9.2 | $14M | 480k | 29.83 | |
Galapagos Nv Call Call Option | 7.8 | $12M | 195k | 62.02 | |
Charles River Laboratories (CRL) | 5.8 | $8.9M | 32k | 283.97 | |
Kalvista Pharmaceuticals (KALV) | 5.6 | $8.7M | 589k | 14.74 | |
Cue Biopharma (CUE) | 4.8 | $7.4M | 1.5M | 4.88 | |
Aldeyra Therapeutics (ALDX) | 4.0 | $6.2M | 1.4M | 4.45 | |
Meiragtx Holdings (MGTX) | 3.4 | $5.3M | 381k | 13.85 | |
Kezar Life Sciences (KZR) | 3.2 | $5.0M | 300k | 16.62 | |
Convey Hldg Parent | 3.2 | $4.9M | 748k | 6.54 | |
Alnylam Pharmaceuticals (ALNY) | 2.4 | $3.7M | 23k | 163.28 | |
Agilon Health (AGL) | 2.3 | $3.5M | 140k | 25.35 | |
Shattuck Labs (STTK) | 2.2 | $3.4M | 799k | 4.26 | |
Rocket Pharmaceuticals (RCKT) | 2.1 | $3.2M | 203k | 15.86 | |
Quidel Corporation | 1.9 | $2.9M | 26k | 112.44 | |
Encompass Health Corp (EHC) | 1.8 | $2.8M | 40k | 71.10 | |
Oscar Health Cl A (OSCR) | 1.5 | $2.4M | 238k | 9.97 | |
Accolade (ACCD) | 1.4 | $2.2M | 124k | 17.56 | |
Select Medical Holdings Corporation (SEM) | 1.4 | $2.2M | 91k | 23.99 | |
Crispr Therapeutics Namen Akt (CRSP) | 1.4 | $2.1M | 34k | 62.76 | |
Inmode SHS (INMD) | 1.2 | $1.8M | 50k | 36.92 | |
Mirum Pharmaceuticals (MIRM) | 1.1 | $1.6M | 74k | 22.02 | |
Globus Med Cl A (GMED) | 0.9 | $1.3M | 18k | 73.78 | |
Silverback Therapeutics (SPRY) | 0.7 | $1.1M | 325k | 3.51 | |
Neogenomics Com New (NEO) | 0.5 | $772k | 64k | 12.15 | |
Organon & Co Put Put Option | 0.5 | $699k | 20k | 34.95 | |
Cognition Therapeutics (CGTX) | 0.4 | $660k | 240k | 2.75 | |
Proqr Thrapeutics N V Shs Euro (PRQR) | 0.3 | $542k | 599k | 0.90 | |
Sio Gene Therapies Common | 0.3 | $449k | 670k | 0.67 | |
Iovance Biotherapeutics (IOVA) | 0.2 | $333k | 20k | 16.65 | |
Cymabay Therapeutics | 0.2 | $292k | 94k | 3.11 |